Use of CTCs to assess response to abiraterone acetate at 12 weeks on therapy

Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …

After 10 years, risk of prostate cancer-specific mortality lower for high-risk patients

A paper presented at the annual meeting of the European Association of Urology (EAU) suggests that high-risk prostate cancer patients < 60 years of age at the time of radical prostatectomy are more likely to die from their cancer than from other causes during the first 10 years after their surgery. But after that, other causes of death become more likely. … READ MORE …

Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Vitamin D as a treatment for low-risk prostate cancer? Not based on these data!

A presentation at a meeting of the American Chemical Society in Denver earlier this week suggested the possibility that men who took 4,000 IU of vitamin D every day for 60 days prior to a radical prostatectomy did better than similar men taking a placebo. … READ MORE …

Will Lu-177-anti-PSMA be the next Xofigo?

Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …

How much time is there to make decisions about treatment for low-risk patients?

In recent years there has been a widely acknowledged, if unconfirmed, assumption that men initially diagnosed with low-risk prostate cancer (clinical stage T1-2a, PSA < 10 ng/ml; and Gleason 3 + 3 = 6 or lower) had plenty of time to come to a good decision about their management options, and did not need to rush such decisions. … READ MORE …

“Normal” sexual functionality after a radical prostatectomy — it’s not very likely

According to a report on the Science Daily web site today, a presentation at the ongoing European Association of Urology (EAU) meeting in Madrid, Spain, suggests that the ability to regain normal erectile and sexual function after a radical prostatectomy is actually rather worse than one might have thought. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,254 other followers